相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1962
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Researchers from the University of Bath and UMass Chan Medical School have identified a molecular navigation system that precisely directs neutrophils to infection sites without damaging healthy tissues. - The study, published in Science Advances, reveals that the TRPV2/CB2R receptor complex acts as an accelerator-brake system, with infected cells releasing hepoxilin A₃ to guide neutrophil migration. - Current anti-inflammatory drugs broadly suppress inflammation throughout the body, causing side effects; this discovery offers a pathway to target inflammation only when and where it occurs. - The research team plans to investigate blocking the hepoxilin A₃ signal pathway as a potential new class of anti-inflammatory drug molecules for chronic gut and lung diseases.
- Riaan Singh Digeorge, age 6, became the first patient worldwide to receive an experimental AAV9 gene therapy for Cockayne syndrome on April 21, 2026, at NewYork-Presbyterian Komansky Children's Hospital. - The treatment was the culmination of a nearly five-year, parent-led effort by Riaan Research Initiative, which raised nearly $4 million and fully funded every step from preclinical studies to clinical administration. - Cockayne syndrome is a severe DNA repair disorder with no FDA-approved treatments, causing brain atrophy, growth failure, and early death, with severely affected children having a life expectancy of 5 to 7 years. - The gene therapy delivers a functional ERCC8/CSA transgene via AAV9 directly to the brain; preclinical studies in mice demonstrated an 8.5-fold lifespan increase, supporting the FDA's clearance of the IND application.
- Etienna Bio has obtained exclusive worldwide rights to intellectual property covering human adipose-derived progenitor cells combined with an adipose-derived hydrogel matrix from UMass Chan Medical School. - The licensed technology harnesses the regenerative potential of a patient's own cells within a biologically compatible matrix for non-therapeutic regenerative and aesthetic applications. - The company plans to advance the platform through staged development with an initial focus on cell-enabled products that leverage autologous biology while avoiding regulatory complexity of gene-modified approaches. - The agreement establishes the scientific foundation for Etienna Bio's platform, combining autologous adipose-derived progenitor cells with a native adipose matrix for differentiated regenerative applications.
- Researchers from Drexel University and UMass Chan Medical School achieved proof-of-principle success with "silence and replace" gene therapy for SPG4, the most common form of hereditary spastic paraplegia. - The viral vector-based approach prevented nerve breakdown and symptoms in a mouse model by silencing mutated SPAST genes and replacing them with healthy versions. - The therapy successfully prevented gait defects and degenerative symptoms when administered to newborn mice before symptom onset. - Translation to human patients faces challenges including precise dosing requirements and the need for combination therapies to address existing nerve damage.
- A five-year, $18 million Department of Defense clinical trial will investigate metformin's potential to treat idiopathic pulmonary fibrosis, a life-threatening condition with median survival of just three to five years. - The groundbreaking study represents an unprecedented partnership between the VA, DOD, and Pulmonary Fibrosis Foundation, integrating 45-55 care centers with 10 VA medical centers nationwide. - Veterans face higher IPF risk than civilians and have been historically underrepresented in clinical trials, making this collaboration critical for expanding treatment access. - The trial will screen 800 patients and randomize 400 high-risk individuals to receive either metformin or placebo, with enrollment expected to begin in early 2026.
- A new post-licensure clinical study published in The Lancet demonstrates that Rabishield, a monoclonal antibody therapy developed by UMass Chan Medical School, offers a safe and effective alternative to traditional rabies treatments. - The study involving over 4,000 patients in India showed that Rabishield plus rabies vaccine was better tolerated with fewer serious side effects compared to traditional equine rabies immunoglobulin treatment. - Both treatment groups developed strong immune responses and no participants developed rabies during the one-year follow-up period, reinforcing the therapy's potential to expand global access to lifesaving rabies treatment. - Rabishield addresses a critical public health need in regions like India, where rabies kills an estimated 20,000 people annually, representing two deaths every hour.
- Tonix Pharmaceuticals has licensed worldwide rights to TNX-4800, a long-acting human monoclonal antibody developed by UMass Chan Medical School for seasonal prevention of Lyme disease. - The single-dose antibody targets outer-surface protein A (OspA) on Borrelia burgdorferi bacteria, blocking their maturation in infected deer ticks and providing immediate protection throughout the entire tick season. - TNX-4800 completed a positive Phase 1 study demonstrating safety, tolerability, and a linear pharmacokinetic-pharmacodynamic-efficacy relationship, with Tonix planning an adaptive Phase 2/3 study. - Approximately 70 million people in the United States live in Lyme disease-endemic areas and could potentially benefit from this prophylactic treatment, as no FDA-approved vaccines or preventive therapies currently exist.
- UMass Chan Medical School has entered a non-exclusive licensing agreement with Hongene Biotech Corporation to produce and distribute extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research applications. - The exNA technology, developed by researchers at the RNA Therapeutics Institute, introduces a proprietary backbone modification that significantly enhances oligonucleotide durability and pharmacokinetics while maintaining compatibility with established siRNA designs. - This partnership aims to accelerate RNA therapeutics research beyond liver-targeted applications, addressing a long-standing delivery challenge in the field where all seven FDA-approved siRNAs currently target only liver cells. - Hongene will leverage its expertise in phosphoramidite manufacturing and oligonucleotide synthesis to make exNA materials available through catalog offerings and custom synthesis services for academic and biopharmaceutical researchers.
- A Phase I/II clinical trial at UMass Chan Medical School demonstrated biochemical correction of GM2 gangliosidosis using dual vector gene therapy with minimal adverse reactions. - Trial participants maintained oral feeding for longer periods and experienced fewer, more controllable seizures compared to typical disease progression. - All nine participants showed increased HexA enzyme production surpassing two times the lower limit of normal, though therapeutic levels were not achieved. - Researchers plan to modify the approach to a single vector system to double therapeutic DNA delivery and enable earlier treatment.
- A comprehensive global study analyzing 607 cases from pharmacovigilance databases reveals CAR-T therapy recipients face an 8.9-fold elevated risk of developing T-cell lymphoma and 3.5-fold higher risk of myelodysplastic syndromes. - Secondary malignancies emerge significantly earlier in CAR-T patients with a median onset of 282 days compared to 526 days in controls, with pediatric patients showing extraordinarily rapid development within just 35 days. - The FDA now mandates lifelong monitoring of CAR-T recipients, while experts recommend enhanced surveillance protocols and informed consent discussions to address these emerging safety concerns. - Multiple mechanisms contribute to secondary cancer risk including insertional mutagenesis from viral vectors, impaired immune surveillance, and clonal hematopoietic expansion following lymphodepleting chemotherapy.
